Autogene cevumeran clinical trials
Also written RO7198457.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses autogene cevumeran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Genentech, Inc. (3) · Hoffmann-La Roche (1) · BioNTech SE (1) · Memorial Sloan Kettering Cancer Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test autogene cevumeran.
- Nov 2026A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerPhase 2 · BioNTech SE
- Nov 2026Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryPhase 1 · Memorial Sloan Kettering Cancer Center
- Nov 2027A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)Phase 2 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses autogene cevumeran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)Active, not recruitingPhase 2Hoffmann-La RocheNCT06534983Written as Autogene Cevumeran
- A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerActive, not recruitingPhase 2BioNTech SENCT04486378Written as RO7198457 intravenous (IV)
- A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACActive, not recruitingPhase 2Genentech, Inc.NCT05968326Written as Autogene cevumeran
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedPhase 1Genentech, Inc.NCT03289962Written as Autogene cevumeran
- A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.CompletedPhase 2Genentech, Inc.NCT03815058Written as Autogene cevumeran
- Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT04161755Written as RO7198457
Given beside what is tested · 1 — autogene cevumeran is usual care or a partner of the new treatment
Codes
What other systems call autogene cevumeran · ClinicalTrials.gg INT017151
- UNII (FDA) L8HDH9IB06AUTOGENE CEVUMERANOne source FDA
- NCI Thesaurus C175745Autogene CevumeranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L8HDH9IB06 | AUTOGENE CEVUMERAN | One source FDA |
| NCI Thesaurus | C175745 | Autogene Cevumeran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.